Satsuma Pharmaceuticals Logo
US80405P1075
A2PQPD
STSA

Satsuma Pharmaceuticals

A carregar cotações...

Previsão

Comprar
  4
Manter
  9
Vender
  0

  • Satsuma Technologie announces auditor change after strategic review

    Satsuma Technologie said that Kreston Reeves LLP has resigned its appointment following discussions as part of a comprehensive strategic review and the appointment of a new leadership team in summer 2025. The board has launched a formal selection process for a new auditor to support the company’s growth plans. A statement from Kreston Reeves on its resignation will be circulated and published in accordance with the Companies Act 2006, and a new appointment will be announced in due course. » Mais em de.investing.com


  • Satsuma Technologie raises £163.6 million through successful convertible bond issuance

    Satsuma Technologie has raised £163.6 million by placing a second secured convertible bond, significantly surpassing its minimum target. The financing attracted prominent investors and allowed some to invest in Bitcoin instead of cash. The funds will be used for business expansion and to strengthen the company's Bitcoin-based treasury strategy. » Mais em de.investing.com


  • Tao Alpha becomes Satsuma Technology and adopts new ticker SATS.L

    Tao Alpha PLC is changing its name to Satsuma Technology PLC and adopting the new ticker symbol SATS.L on the London Stock Exchange. The rebranding is intended to highlight the company's focus on decentralized AI services and a Bitcoin-based treasury strategy, while existing shareholder rights remain unaffected. CEO Matthew Lodge emphasizes that this marks a step into a new phase of operational maturity. » Mais em de.investing.com

Em 2014, Satsuma Pharmaceuticals já distribuiu € 0,29 em dividendos. A última distribuição ocorreu em abril de 2014.

Dados financeiros da empresa

No último ano, Satsuma Pharmaceuticals registou receitas de € 0 e um ganho líquido de -€ 64,48 mi
(EUR) 2022
YoY
Receitas 0 -
Ganho bruto 0 -
Ganho líquido -64,48 mi 43,02%
EBITDA -54,36 mi 22,13%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 32,39 mi
Número de ações
33,15 mi
Máximo/mínimo de 52 semanas
€ 7,18 - € 0,52
Dividendos Não
Beta
0,10
PER (PE Ratio)
-0,51
PEG (PEG Ratio)
0,05
P/VC (PB Ratio)
-0,17
P/V (PS Ratio)
0,00

Perfil da empresa

Satsuma Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige therapeutische Produkte für die akute Behandlung von Migräne entwickelt. Der führende Produktkandidat des Unternehmens ist STS101, eine Arzneimittel-Geräte-Kombination aus einer patentrechtlich geschützten Trockenpulverformulierung von Dihydroergotaminmesylat, die sich in SUMMIT-Phase-3-Wirksamkeitsstudien befindet und mit einem patentrechtlich geschützten, vorgefüllten Einweg- und Nasenspritzgerät selbst verabreicht werden kann. Satsuma Pharmaceuticals, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Nome
Satsuma Pharmaceuticals
CEO
John A. Kollins MBA
Sede South San Francisco, ca
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
13/09/2019
Colaboradores 25

Símbolos de ticker

Bolsa Símbolo
NASDAQ
STSA
🍪

Parqet  utiliza cookies. Saber mais